...
首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer.
【24h】

Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer.

机译:miRNA主调节剂Drosha和Dicer的下调与乳腺癌的特定亚组有关。

获取原文
获取原文并翻译 | 示例
           

摘要

Down-regulation of Drosha and Dicer has been suggested to be of prognostic value in some cancers. The aims of our study were to investigate the down-regulation of Drosha and Dicer in breast cancers and its associations with clinicopathological features, molecular subtypes and outcome. Drosha and Dicer expression was assessed with real-time RT-PCR in 245 patients with breast cancer receiving adjuvant anthracycline-based chemotherapy and compared to expression levels of normal breast tissue. Drosha down-regulation was observed in 18% of cases and was associated with high grade, high Ki-67, lack of Bcl2 expression, HER2 over-expression and gene amplification and TOPO2A gene amplification. Dicer down-regulation was found in 46% of cases and was associated with lack of expression of ER, PR and Bcl2 and with high grade, high Ki-67, triple-negative and basal-like phenotypes. Drosha and Dicer were concurrently down-regulated in 15% of cases and significantly associated with high grade and high Ki-67 index. No significant associations between down-regulation of Drosha and/or Dicer and outcome were observed. Our results suggest that down-regulation of Drosha and/or Dicer is not robustly associated with the outcome of breast cancer patients treated with adjuvant anthracycline-based chemotherapy but preferentially observed in distinct subgroups of breast cancer.
机译:Drosha和Dicer的下调在某些癌症中具有预后价值。我们研究的目的是研究乳腺癌中Drosha和Dicer的下调及其与临床病理特征,分子亚型和预后的关系。通过实时RT-PCR对245例接受蒽环类辅助化疗的乳腺癌患者的Drosha和Dicer表达进行了评估,并与正常乳房组织的表达水平进行了比较。在18%的病例中观察到Drosha下调,与高等级,高Ki-67,缺乏Bcl2表达,HER2过表达和基因扩增以及TOPO2A基因扩增有关。在46%的病例中发现切块机下调,并与ER,PR和Bcl2的缺乏表达以及高,高Ki-67,三阴性和基底样表型有关。在15%的病例中,Drosha和Dicer同时被下调,并且与高等级和高Ki-67指数显着相关。在Drosha和/或Dicer的下调与结局之间未发现显着关联。我们的结果表明,Drosha和/或Dicer的下调与以辅助蒽环类为基础的化学疗法治疗的乳腺癌患者的预后没有强相关性,但优先在不同的乳腺癌亚组中观察到。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号